MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. - Wikidata - awgldk - TriplyDB

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

http://www.wikidata.org/entity/Q37964985

about

Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis Anorectal dysfunction in multiple sclerosis: a systematic review Optimizing treatment success in multiple sclerosis Global and 3D spatial assessment of neuroinflammation in rodent models of Multiple Sclerosis Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis Clinical relevance of brain volume measures in multiple sclerosis.Nonconventional MRI and microstructural cerebral changes in multiple sclerosis.Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives Oral contraceptives combined with interferon β in multiple sclerosis.Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.Disrupted topological organization of structural and functional brain connectomes in clinically isolated syndrome and multiple sclerosis.Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis.Nanomaterial applications in multiple sclerosis inflamed brain.Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice.Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study.Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.A Model of Population and Subject (MOPS) Intensities With Application to Multiple Sclerosis Lesion Segmentation.An adaptive clinical trials procedure for a sensitive subgroup examined in the multiple sclerosis context.MRI-based clinical trials in relapsing-remitting MS: new sample size calculations based on a longitudinal model.Defining and scoring response to IFN-β in multiple sclerosis.Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.Multicenter Validation of Mean Upper Cervical Cord Area Measurements from Head 3D T1-Weighted MR Imaging in Patients with Multiple Sclerosis.Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.Disrupted Module Efficiency of Structural and Functional Brain Connectomes in Clinically Isolated Syndrome and Multiple Sclerosis.Vitamin A: yet another player in multiple sclerosis pathogenesis?

P2860

Q22066266-76F9B2A6-79DE-4D3B-BEA9-C70F90F7ABFE Q24621445-AA2DABFA-9488-466A-B3D9-9F4E1D3CFB86 Q26771968-DD9DE052-F40A-48F3-A0D0-03D59C195CD8 Q27304718-C717DBED-08E5-4CD9-A06B-BDDAE6F1719E Q30582882-3C26FE94-9286-493D-919E-96F32A8B7637 Q30738659-A4373ED0-86B7-443A-AC2E-4FCEC8C4007F Q31015218-436A5CEF-F324-4BF1-BD60-E58A33FF744C Q35182733-1DAEEF3F-57D9-4602-926D-82EE30937472 Q35764738-8EEFF621-FF63-4C86-9343-6C4279F93887 Q36731490-32F8780E-583B-4514-A140-80A8159C1E92 Q37022572-42BEF608-4E9C-443E-A7D3-EC07CEDD0570 Q37086785-602F33E4-A22B-4E07-8C4F-E0FF45B276AC Q37360536-C554817C-1A14-483A-A93E-2E96FF1E1265 Q37504560-85C28DA0-49BE-4210-803B-E3B53A6D94EA Q38330408-F5683D38-768F-4955-A623-A3A068C7AE4A Q38587671-D14F3C5C-F7D6-4698-8556-AFEC7CB85529 Q39606176-45FBAF0A-081D-4885-9C8D-5EA897E5393B Q41126166-5540C59C-C218-40F5-9B0B-868D2900D1D5 Q41535507-02155094-C0FB-4503-987A-64F9087D5177 Q43763237-F990D313-3BCC-4B7C-92E2-A7A6C14E0E50 Q45988953-7F6ED9A6-7FD3-4410-B047-DF3429E3F409 Q46023940-205AAAF9-DE2B-4E63-8AE0-EE9AC95B633F Q47878933-AECCB717-E335-49F9-A2EA-87B70A35058A Q48090675-4B2913D2-5F0B-4C5C-A995-7DA991FC3432 Q51154524-A1A35303-6DF0-49EF-A6EA-5CC237CF17A6 Q52564671-17A82730-9FB1-4CD4-9A57-EE45FFA7F045 Q57911740-19849844-C416-4DC2-AF81-44723D98B50D

P2860

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

http://www.wikidata.org/entity/Q37964985

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

@en

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

@nl

type

label

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

@en

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

@nl

prefLabel

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

@en

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

@nl

P1433

Q37964985-21C46C1E-6E8E-4C1A-B7F5-75F635148451

P1476

Q37964985-1BA28074-0EAE-446E-9956-8AFE9423A2B3

P2093

Q37964985-1D659C3B-25C4-427A-9B0C-1C05324ED2A9

Q37964985-204A7123-9815-4514-B6E3-077ACD1EFDF4

Q37964985-3311F409-3293-4454-AFA2-D50A0D45FEC6

Q37964985-40036418-5E23-4D81-A760-0FD6FA8483D0

Q37964985-64F2708F-C4F4-4AC6-842D-92FD681DD9FC

Q37964985-6F891017-D734-44F4-A8CA-9097AD2D7EC3

Q37964985-86AE911E-07C9-4A1A-9581-D4FC45FD1FED

Q37964985-9146EBF2-2A3E-4787-97E5-2C7D9A89798F

Q37964985-C9BEDB62-EADE-480C-BC71-113CD7C6EE82

Q37964985-CCD24106-A25F-42D8-8B9C-CE13C575A050

P2860

Q37964985-070697D8-3DFB-4B02-B18E-EE8C5195BF59

Q37964985-0FA777B9-8205-4829-B8C6-2B6B5BAC5EB8

Q37964985-1114E3F3-5BDE-4753-B3DB-89C4E6CBC528

Q37964985-13B97352-E8D7-4727-B523-55A6973D37D0

Q37964985-1B248361-25CA-418B-8996-58B726FF33BC

Q37964985-1E34756D-A97C-42F9-ACFE-F2495B68B6F9

Q37964985-22B74801-85AB-442A-A5B9-232A90BAB8EB

Q37964985-2535D2E2-22F3-4BE0-B3DC-E14B2C2F632B

Q37964985-27705884-3ACF-4738-A3AE-48855B4BD566

Q37964985-28F20E5E-66E9-435C-B245-C7EB2CD31D6F

P2888

Q37964985-001FFE4A-3AEA-4915-94D6-289BD8946F76

P304

Q37964985-92E9DAEC-B011-4D45-8AA6-FA383E54E7DD

P31

Q37964985-672E8C0F-DA90-43B0-8640-B1F46CD809BE

P356

Q37964985-51E547A7-FB47-4D52-86BA-B1E400D72117

P407

Q37964985-C5FE8213-A055-4D42-AC1B-11350195A5C8

P433

Q37964985-C4ED9DCB-193B-46BB-865C-D23579DFE8E0

P478

Q37964985-5E372EAE-A22F-4D63-86FB-C53CE60B72EA

P50

Q37964985-6CD71438-328A-49D3-B1C7-24E8FAA0F480

Q37964985-BDD6D320-C676-446F-93D8-26323CBD13F1

Q37964985-F9BE54BF-6E76-42FB-9E9F-6459E9FB2DCA

P577

Q37964985-CC486A3D-DD6B-40CB-808A-72D6DDD2F1E7

P6179

Q37964985-911BC804-1352-4205-8714-68F09366157B

P698

Q37964985-640B6CCE-44AD-4D36-AE9C-D317971FDC47

P921

Q37964985-8F528809-ABD7-46D8-85F1-4C8FB8D36F90

P356

NRNEUROL.2011.190

P1433

Nature Reviews Neurology

P1476

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

@en

P2093

Chris H Polman

http://www.w3.org/2001/XMLSchema#string

David H Miller

http://www.w3.org/2001/XMLSchema#string

David K Li

http://www.w3.org/2001/XMLSchema#string

Ernst W Radue

http://www.w3.org/2001/XMLSchema#string

Jack H Simon

http://www.w3.org/2001/XMLSchema#string

John Petkau

http://www.w3.org/2001/XMLSchema#string

Marco Rovaris

http://www.w3.org/2001/XMLSchema#string

Maria P Sormani

http://www.w3.org/2001/XMLSchema#string

Massimo Filippi

http://www.w3.org/2001/XMLSchema#string

Nicola de Stefano

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Identification of Intracortical Lesions in Multiple Sclerosis with Phase-Sensitive Inversion Recovery in Combination with Fast Double Inversion Recovery MR Imaging

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

Advances in functional and structural MR image analysis and implementation as FSL

P2888

nrneurol.2011.190

P304

13-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRNEUROL.2011.190

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Frederik Barkhof

P577

2011-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1038377997

http://www.w3.org/2001/XMLSchema#string

P698

22143362

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis